120 related articles for article (PubMed ID: 32267557)
1. The impact of age and comorbidity in advanced or recurrent biliary tract cancer receiving palliative chemotherapy.
Takahara N; Nakai Y; Saito K; Sasaki T; Suzuki Y; Inokuma A; Oyama H; Kanai S; Suzuki T; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Tada M; Isayama H; Koike K
J Gastroenterol Hepatol; 2020 Oct; 35(10):1828-1835. PubMed ID: 32267557
[TBL] [Abstract][Full Text] [Related]
2. Patients with recurrent biliary tract cancer have a better prognosis than those with unresectable disease: retrospective analysis of a multi-institutional experience with patients of advanced biliary tract cancer who received palliative chemotherapy.
Ikezawa K; Kanai M; Ajiki T; Tsukamoto T; Toyokawa H; Terajima H; Furuyama H; Nagano H; Ikai I; Kuroda N; Awane M; Ochiai T; Takemura S; Miyamoto A; Kume M; Ogawa M; Takeda Y; Taira K; Ioka T
J Hepatobiliary Pancreat Sci; 2014 Feb; 21(2):98-104. PubMed ID: 23798367
[TBL] [Abstract][Full Text] [Related]
3. CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.
Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Noguchi K; Suzuki T; Nakamura T; Sato T; Ishigaki K; Hakuta R; Takeda T; Uchino R; Mizuno S; Kogure H; Tada M; Koike K
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1105-1112. PubMed ID: 29038848
[TBL] [Abstract][Full Text] [Related]
4. The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuvant chemotherapy.
Aoyama T; Yamamoto N; Kamiya M; Murakawa M; Tamagawa H; Sawazaki S; Numata M; Kobayashi S; Ueno M; Morimoto M; Shiozawa M; Yukawa N; Oshima T; Yoshikawa T; Rino Y; Masuda M; Morinaga S
J Cancer Res Ther; 2020 Dec; 16(Supplement):S116-S121. PubMed ID: 33380664
[TBL] [Abstract][Full Text] [Related]
5. Age-adjusted Charlson Comorbidity Index is a valuable prognostic tool in operable soft tissue sarcoma of trunk and extremities.
Telli TA; Alan O; Demircan NC; Sariyar N; Arikan R; Basoglu T; Yasar A; Celebi A; Isik S; Sofulu O; Erol B; Turkoz HK; Ozgen Z; Ercelep O; Dane F; Yumuk PF
Orthop Traumatol Surg Res; 2023 May; 109(3):103491. PubMed ID: 36455864
[TBL] [Abstract][Full Text] [Related]
6. Comparative outcomes of elderly and non-elderly patients receiving first-line palliative chemotherapy for advanced biliary tract cancer.
Kou T; Kanai M; Ikezawa K; Ajiki T; Tsukamoto T; Toyokawa H; Yazumi S; Terajima H; Furuyama H; Nagano H; Ikai I; Kuroda N; Awane M; Ochiai T; Takemura S; Miyamoto A; Kume M; Ogawa M; Takeda Y; Taira K; Ioka T
J Gastroenterol Hepatol; 2014 Feb; 29(2):403-8. PubMed ID: 23869919
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the impact of comorbidity on the survival of cancer patients treated by palliative care teams.
Calvo-Espinos C; De Gaona-Lana ER; Gonzalez-Anguren C; Lama-Gay M
Palliat Support Care; 2015 Aug; 13(4):1049-55. PubMed ID: 26165849
[TBL] [Abstract][Full Text] [Related]
8. The age-adjusted Charlson comorbidity index as a predictor of survival in surgically treated vulvar cancer patients.
Di Donato V; Page Z; Bracchi C; Tomao F; Musella A; Perniola G; Panici PB
J Gynecol Oncol; 2019 Jan; 30(1):e6. PubMed ID: 30479090
[TBL] [Abstract][Full Text] [Related]
9. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
[TBL] [Abstract][Full Text] [Related]
11. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases.
Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Oyama H; Kanai S; Suzuki T; Sato T; Hakuta R; Ishigaki K; Takeda T; Saito T; Mizuno S; Kogure H; Tada M; Koike K
Invest New Drugs; 2018 Dec; 36(6):1093-1102. PubMed ID: 30324343
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
Suidan RS; Leitao MM; Zivanovic O; Gardner GJ; Long Roche KC; Sonoda Y; Levine DA; Jewell EL; Brown CL; Abu-Rustum NR; Charlson ME; Chi DS
Gynecol Oncol; 2015 Aug; 138(2):246-51. PubMed ID: 26037900
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Impact of the Age-adjusted Charlson Comorbidity Index on Esophageal Cancer Patients Who Receive Curative Treatment.
Aoyama T; Atsumi Y; Kawahara S; Tamagawa H; Tamagawa A; Ozawa Y; Maezawa Y; Kano K; Murakawa M; Kazama K; Segami K; Hara K; Numata M; Oshima T; Yukawa N; Masuda M; Rino Y
In Vivo; 2020; 34(5):2783-2790. PubMed ID: 32871815
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of the Age-Adjusted Charlson Comorbidity Index (ACCI) on Short- and Long-Term Outcome in Patients with Advanced Primary Epithelial Ovarian Cancer.
Kahl A; du Bois A; Harter P; Prader S; Schneider S; Heitz F; Traut A; Alesina PF; Meier B; Walz M; Brueckner A; Groeben HT; Brunkhorst V; Heikaus S; Ataseven B
Ann Surg Oncol; 2017 Nov; 24(12):3692-3699. PubMed ID: 28871563
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer.
Phillips A; Singh K; Pounds R; Sundar S; Kehoe S; Nevin J; Elattar A; Balega J
J Obstet Gynaecol; 2017 Nov; 37(8):1070-1075. PubMed ID: 28741395
[TBL] [Abstract][Full Text] [Related]
16. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer.
Koppie TM; Serio AM; Vickers AJ; Vora K; Dalbagni G; Donat SM; Herr HW; Bochner BH
Cancer; 2008 Jun; 112(11):2384-92. PubMed ID: 18404699
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis.
Ji JH; Kim YS; Park I; Lee SI; Kim RB; Park JO; Oh SY; Hwang IG; Jang JS; Song HN; Kang JH
Cancer Res Treat; 2018 Jul; 50(3):791-800. PubMed ID: 28838033
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy.
Saisho T; Okusaka T; Ueno H; Morizane C; Okada S
Hepatogastroenterology; 2005; 52(66):1654-8. PubMed ID: 16334750
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
